- Will CAR-NK Cancer Therapy Surpass High-Cost CAR-T Immunotherapy?
- What is the role of Platelet Dynamics in Cancer Progression?
- Biomarkers can detect rapid aging of organs and disease risks
- Avoiding “Off-Target” Effects: Researchers Enhance the Safety of Future mRNA Therapies
- Japan: Sales Halted for ‘Cannabis Gummies’ as Health Issues Mount
- Evaluation of the carcinogenicity of organic fluorine compounds raised by WHO subsidiary
AACR: New cancer vaccine: 4 patients survived for nearly 2.5 years
AACR: New cancer vaccine: 4 patients survived for nearly 2.5 years. AACR annual meeting news: With the new cancer vaccine, 4 patients survived cancer-free for nearly 2.5 years after receiving treatment!
As one of the important branches of immunotherapy, cancer vaccine also attracted everyone’s attention at this AACR annual meeting.
Established in 1907, the AACR Association is the world’s earliest and largest scientific organization dedicated to comprehensive, innovative and high-level cancer research. It organizes high-level annual conferences every year, and many large-scale research results will be announced at the conference. . This year’s AACR annual meeting has started on April 10, 2021 and will end on April 15, 2021. Due to the continuation of the global epidemic, this annual meeting will be held online.
The AACR annual meeting did not end, but it has brought us many blockbuster advances in the field of cancer treatment, including the latest cancer vaccine development we are going to talk about today. This personalized cancer vaccine developed by the Sinai team with the aid of a computer platform not only has significant therapeutic effects, but also has good safety.
In the previous article, we also said that the current cancer immunotherapy includes CAR-T cell therapy, PD-1/PD-L1 inhibitors, oncolytic viruses, and cancer vaccines. Among them, the most popular natural number CAR-T cell therapy and PD-1/PD-L1 inhibitors are two, but cancer vaccines are also one of the key areas of attention. For the knowledge of cancer vaccines, you can click on the comics to learn more.
After all, if you can avoid cancer with one shot like other preventive vaccines, then it is naturally the best.
In fact, cancer vaccines are divided into two categories. One is the preventive vaccine, which is what we usually know. At present, there is only one cancer vaccine in the world, which is HPV vaccine (recommended age-appropriate Men and women are vaccinated against HPV); the other type is a therapeutic vaccine, which is the protagonist this time-by vaccinating cancer vaccines to trigger an immune response to eliminate tumors.
In order to make the cancer vaccine safer and more effective, the researchers used the computer at Mount Sinai to optimize the vaccine. Cancer vaccines need to bind to specific tumor targets and induce the immune system to recognize the corresponding targets, thereby attacking and killing cancer cells. Researchers sequenced the patient’s tumor type, DNA, and target, and the computer helped identify and confirm the priority of the corresponding tumor target, thereby creating a more effective cancer vaccine.
In this study, a total of 13 patients received the cancer vaccine treatment of the Sinai team, including 10 patients with solid tumors and 3 patients with multiple myeloma. This is a phase 1 clinical trial, the main purpose of which is to explore the safety of cancer vaccines.
However, in actual treatment, the overall tolerance of the patient’s vaccine is very good, and only about one-third of patients have a slight reaction at the injection site. Correspondingly, after 880 days of follow-up, 4 patients still survived cancer-free, and 4 patients were continuing to receive treatment. On the whole, the patient’s treatment effect is also very good.
Generally speaking, some adjuvants are added to cancer vaccines to enhance the effect of immunotherapy, so that cancer vaccines can better induce immune responses. According to the information disclosed by the Mount Sinai team, a number of solid tumor treatments are currently entering phase 1 clinical trials, including: glioblastoma, bladder cancer, prostate cancer, and myeloproliferative tumors.
After the safety is confirmed in Phase 1, Phase 2 clinical trials will mainly verify the effectiveness of the therapy, and more patients will be enrolled. As one of the important branches of immunotherapy, cancer vaccine also attracted everyone’s attention at this AACR annual meeting. At this AACR annual meeting, immunotherapy is still an undisputed popular therapy. I believe that this AACR annual meeting will bring us more surprise advances in immunotherapy.
(source:internet, reference only)